The authors reply

New England Journal of Medicine

Volumn 372, Issue 14, 2015, Pages 1373-1374

  Mauri, Laura ^a   Yeh, Robert W ^b   Kereiakes, Dean J ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c CHRIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EVEROLIMUS; PACLITAXEL; PLACEBO; PRASUGREL; PROTON PUMP INHIBITOR; THIENOPYRIDINE DERIVATIVE; ANTITHROMBOCYTIC AGENT; PIPERAZINE DERIVATIVE; THIOPHENE DERIVATIVE; TICLOPIDINE;

CANCER MORTALITY; DRUG ELUTING STENT; HEART INFARCTION; HUMAN; LETTER; NEOPLASM; PRIORITY JOURNAL; RISK REDUCTION; SECONDARY PREVENTION; STENT THROMBOSIS; TREATMENT DURATION; ANALOGS AND DERIVATIVES; FEMALE; MALE; THROMBOSIS;

ASPIRIN; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; THIOPHENES; THROMBOSIS; TICLOPIDINE;

EID: 84926394228     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1501195     Document Type: Letter

References (2)

1. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012;379: 1393-402.
2. Schulz-Schüpke S, Byrne RA, Ten Berg JM, et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 versus 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J 2015 January 23 (Epub ahead of print).